GlaxoSmithKline Recalls Flu Vaccine Due to Potency Problem GlaxoSmithKline is recalling remaining doses of a popular four-in-one flu vaccine because of effectiveness problems. The company alerted U.S. customers Tuesday that the vaccine can lose potency over time and fail to adequately protect against some strains of the flu. The Flulaval Quadrivalent Thimerosal-free vaccine in prefilled syringes is designed to protect against four strains of influenza virus. But Glaxo said in a letter it "cannot rule out potential suboptimal protection" in people who received the vaccine in early January or later. The letter was sent to about 1,000 customers throughout the U.S., including wholesale distributors, pharmacies, government agencies and physicians. Flu jab given to millions is 'useless' The flu vaccine given to millions of people in the UK barely works, health officials have admitted, amid warnings that the number of deaths this winter will be the worst for 15 years. Public Health England (PHE) warned that the main strain of influenza in circulation - which is particularly lethal among the elderly – has mutated from the type that was used in the jab. As a result, it is working in just three per cent of people given it, when it is normally effective in around half of cases. Eco comments: Because of lower immune resiliency in ME/CFS patients. It's best to get a script for Tamiflu or Relenza to have on hand, just in case one is exposed to the flu virus.